# 547. An Open-label Multicenter Phase 2 Trial of Telacebec for Adults with Buruli ulcer: the TREAT-BU Trial

## TL;DR

A new antibiotic, telacebec, shows promise as a safe and effective single-drug treatment for Buruli ulcer in adults.

## Contribution

Telacebec is a novel antibiotic that may replace prolonged combination therapies for Buruli ulcer.

## Key findings

- Telacebec was well-tolerated with no serious adverse events in 40 adult participants.
- 97.5% of Buruli ulcer lesions healed without recurrence after 28 days of telacebec treatment.
- No drug-related mutations or need for surgery were observed during follow-up.

## Abstract

Current WHO recommended treatment for Buruli ulcer (BU), caused by Mycobacterium ulcerans, is highly effective but requires a prolonged duration of combination antibiotics that in adults are often poorly tolerated with complex drug interactions, and are associated with prolonged wound healing. Telacebec is a novel, first-in-class antibiotic that demonstrates rapid killing of M. ulcerans in vitro and in animal models, and has shown a favorable safety profile in early human studies. It provides the potential for single-drug treatment for BU with reduced duration, side-effects, drug interactions, pill burden and healing times. We aimed to evaluate the safety, tolerability, efficacy and pharmacokinetics of this novel treatment for BU.

A phase 2 multicenter open-label trial of telacebec 300 mg once daily for 28 days is being conducted at two centres in Victoria, Australia. The study includes adults weighing ≥45 kg with PCR positive M. ulcerans lesions that are WHO category I- III if ≤10cm diameter. Primary outcome is complete BU lesion healing rate by 52 weeks after treatment initiation, without relapse and/or curative intent excision surgery.

Forty participants were enrolled from July to December 2024 with a median age of 60 (IQR 44–72) years and 29 (73%) were male. WHO category I, II and III lesions were represented in 32 (80%), 4 (10%) and 4 (10%) participants respectively. Median weight was 85 (IQR 74–92) kg. All participants completed treatment without interruption or discontinuation and there were no drug-related serious adverse events reported. Commonly reported treatment emergent adverse events included headache (18%), lethargy (10%), dizziness (8%), nausea (8%) and diarrhea (8%); all were mild. No patients required surgery. Five (12.5%) swabs taken from lesions after 4 weeks of treatment were culture positive for M. ulcerans at 12 weeks incubation; no telacebec associated mutations in the qcrB gene were detected and all lesions have healed. All patients have completed at least 34 weeks follow-up. To date 39 (97.5%) lesions have healed with no recurrences.

Early experience suggests that 28 days of telacebec monotherapy may offer a safe, well-tolerated, effective and convenient treatment option for BU.

All Authors: No reported disclosures